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Abstract
Background: Triosephosphate isomerase (TPI) is a central and conserved glycolytic enzyme. In
humans, TPI is encoded by a single gene on 12p13, and associated with a rare genetic disorder, TPI
deficiency. Reduced TPI activity can increase specific oxidant resistances of model organisms and
TPI null-alleles have been hypothesized to promote a heterozygote advantage in man. However,
comprehensive genetic information about the TPI1 locus is still lacking.
Results: Here, we sequenced the TPI1 locus in a sample of 357 German long-lived individuals (LLI)
aged 95 to 110 years. We identified 17 different polymorphisms, of which 15 were rare and
previously unknown. The two remaining SNPs occurred at much higher frequency and were tested
for association with the longevity phenotype in larger samples of LLI (n = 1422) and younger
controls (n = 967). Neither of the two markers showed a statistically significant difference in allele
or genotype frequency between LLI and control subjects.
Conclusion: This study marks the TPI1 locus as extraordinarily conserved, even when analyzing
intronic and non-coding regions of the gene. None of the identified sequence variations affected
the amino acid composition of the TPI protein and hence, are unlikely to impact the catalytic activity
of the enzyme. Thus, TPI variants occur less frequent than expected and inactive alleles are not
enriched in German centenarians.
Background
Triosephosphate isomerase (TPI, TIM; EC 5.3.1.1) is a
cytoplasmic enzyme of the carbohydrate metabolism and
catalyzes the glycolytic interconversion of the three-car-
bon sugars glyceraldehyde-3-phosphate and dihydroxyac-
etone phosphate in an extraordinarily efficient way [1,2].
In most species, this enzyme is present as a soluble, stable
dimer and appears to be highly conserved among all king-
doms. In humans, the TPI enzyme is encoded by a single
gene located at chromosome 12p13 [3]. This gene is asso-
ciated with a rare genetic disorder, triosephosphate iso-
merase deficiency, initially described in 1965 [4], that is a
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unique glycolytic enzymopathy with autosomal recessive
inheritance characterized by chronic haemolytic anaemia,
cardiomyopathy, susceptibility to infections, severe neu-
rological dysfunction, and, in most cases, death in early
childhood [5,6]. The disease pathology correlates with a
drastic decrease in the enzymatic activity of TPI and con-
sequently, increased concentration of the TPI substrate
dihydroxyacetone phosphate (reviewed in [6,7]). Analysis
of the pathogenic mutations in a recombinant yeast
model revealed that the decrease in TPI activity is not
based on an per se inactive enzyme species, but likely the
consequence of a misguided regulatory mechanism that
might be caused by altered dimerization of the pathogenic
TPI isoforms [8]. These results are in good agreement with
previous observations made in mice showing that a com-
plete lack of TPI activity (homozygous TPI null alleles)
causes embryonic lethality at the earliest stages [9].
Accordingly, a recent study in Drosophila reveals that the
pathogenesis of TPI deficiency could result from proteas-
omal degradation of the apparently functional enzyme
[10].
Remarkably, in several human populations, unexpected
high frequencies of individuals exhibiting about 50% of
the normal TPI activity have been detected [11-15], indi-
cating heterozygously inherited null alleles. The estimated
allele frequencies of these ranged from 0.002 (Europeans)
to 0.02 (Afro-Americans) [11-15], but the underlying
molecular genetic defects have so far remained unknown.
An association of reduced TPI activity with three allelic
variants of the TPI promoter region (located at pos. -5, -8,
and -24) in African-Americans [11] could not be con-
firmed in a follow-up study; these single nucleotide poly-
morphisms (SNPs) turned out to represent common
haplotypes in another African-American sample [16].
Keeping in mind the aforementioned lethality of
homozygous null alleles, the high frequency of the heter-
ozygous null alleles may indicate an evolutionary advan-
tage of a TPI+/0  genotype [8,9,11]. The nature of this
potential heterozygote advantage has not yet been eluci-
dated, however, reduced TPI activity mediates cellular
resistance to conditions of oxidative stress [8]. This phe-
notype has been studied in yeast and in C. elegans, and is
based on a metabolic re-routing between glycolysis and
the associated pentose phosphate pathway [17]. This
observation is of basic biological interest since these two
metabolic pathways are not only implicated in the cellular
energy supply, but are also involved in cell growth, cell
death and in the ageing process. Thus, the TPI1 locus rep-
resents an interesting target for genetic analysis, especially
for studies focusing on ageing or oxidative-stress proc-
esses. However, at least for European populations, com-
prehensive sequence information about allelic TPI
variants and their distributions and frequency is still lack-
ing. Moreover, since oxidative stress is a key player in the
ageing process – and model organisms with reduced TPI
activity are more resistant to it – it is also of viable interest
to ascertain the distribution and frequency of allelic TPI
variants in humans who have attained an exceptional life
span above average. Therefore, we re-sequenced the TPI1
locus in an extended sample of 357 German long-lived
individuals aged 95 to 107 years. Two of the identified fre-
quent polymorphisms were subsequently tested for asso-
ciation with the longevity phenotype.
Methods
Subjects
In this study, we sequenced the TPI1 locus from DNA
samples of 357 German long-lived individuals (LLI)
drawn from a larger collection [18]. The study participants
had a mean age of 97.2 years at ascertainment ranging
from 95 to 107 years; about 71% of them were female.
The subsequent association analyses were performed on
the entire collection comprising 1422 LLI (mean age: 98.8
years, age range: 95–110 years) and 967 younger controls
(mean age: 66.8 years, ranging from 60 to 75 years). The
cases were specifically matched to the controls by ethnic-
ity, gender and geographic origin within Germany. The
DNA collections and the recruitment procedures were
reported in detail elsewhere [18]. DNA was isolated from
blood samples of all participants using standard methods.
All subjects gave written informed consent prior to partic-
ipation. The study was approved by the Ethics Committee
of the University Hospital Schleswig-Holstein in Kiel.
Analysis of genetic variation by re-sequencing
The TPI1 locus including all introns and exons was dis-
sected into suitable polymerase-chain-reaction (PCR)
fragments that ranged in size from 454 to 800 bps (details
of PCR are provided in Supplementary Material). All
primers were designed with Primer3 and all resulting frag-
ments were amplified by PCR with Taq DNA Polymerase
(total reaction volume, 20 μl) supplemented with a
home-made PCR enhancer as described [19]. Both strands
were routinely amplified and sequenced to ensure maxi-
mal accuracy in variation analysis. PCR primers were also
used as sequencing primers. Additional internal primers
were used for PCR products longer than 600 bp to ensure
that there was double-stranded sequence information for
the whole PCR fragment. Sequencing was performed on
ABI3730xl automated DNA sequencers with the BigDye
Terminator V3.1 Cycle Sequencing Kit (Applied Biosys-
tems). The complete coding, flanking 5' and 3' untrans-
lated regions of TPI1 and 100 bp of the promoter region
were sequenced and compared with the reference
sequence (GenBank accession number U47924).
Polyphred software together with Phred, Phrap, Repeat-
Masker, and Consed were used to detect polymorphisms.BMC Genetics 2008, 9:38 http://www.biomedcentral.com/1471-2156/9/38
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Of the 357 DNA samples, all genotypes (92.4 to 96.6%)
at each polymorphic site of TPI1 were determined with
maximal accuracy and included in the analysis.
Genotyping
The SNP rs2071069 was genotyped using the SNPlex™
Genotyping System and SNP rs2071065 (hCV15868213)
with a TaqMan® SNP Genotyping Assay (Applied Biosys-
tems, Foster City, USA). Single-marker case-control asso-
ciation analyses were performed with the software
program Genomizer [20].
Results and Discussion
This study presents the first molecular analysis of the
genetic variability of the human TPI1 gene locus in a large
set of long-lived individuals. As illustrated in figure 1, the
TPI1 locus is composed of 7 exons and spans a genomic
region of 3.2 kb. This allowed high sequence coverage by
using only 6 PCR fragments (please see Additional file 1
for the primer sequences used). We detected 17 different
mutations or polymorphisms in the analyzed region of
the TPI1 gene relative to the reference sequence (Table 1).
Only two of them (rs2071065 and rs2071069) were pre-
viously known, whereas the other 15 were not identified
in a dbSNP search. Out of these, 15 SNPs were rare, in fact,
11 variants occurred only once. Of note, one subject had
three of these private mutations. None of the previously
detected SNPs in African-Americans [11] were seen in the
German sample.
As listed in Table 1, the two known TPI1 variants
(rs2071065 and rs2071069) had a much higher allele fre-
quency (0.270 and 0.260, respectively) compared to the
others. One of these (SNP rs2071069) has been studied
previously (termed TPI 2898 in [21] and TPI 2262 in
[22]). Although its low frequency in the random sample,
this SNP was found in all subjects having inherited the
most common disease allele (TPI 1591C, encoding
TPIGlu104Asp). This discovery allowed the authors to
conclude that all TPIGlu104Asp subjects are descendants
of a common ancestor that lived in today's France or Eng-
land more than 1000 years ago [21,22].
The detected allele-frequencies of rs2071065 and
rs2071069 prompted us to test whether there is a genetic
association between the SNP alleles and the longevity
phenotype in larger samples of LLI (n = 1422) and control
individuals (n = 967). The genotype analyses revealed
SNP frequencies that were quite similar to those deter-
mined by sequencing. SNP rs2071065 showed an allele
frequency of 0.30 in the LLI and 0.28 in the controls,
respectively; the second SNP rs2071069 had a frequency
of 0.29 in the LLI and 0.27 in controls. However, neither
of the two markers showed a statistically significant differ-
ence in allele or genotype frequency between LLI and con-
trol subjects, using the entire collection or subsamples
stratified for gender (P > 0.05).
Fourteen of the detected mutations were located in
intronic and three in exonic regions. However, none of
the detected variants seem to affect the amino acid
sequence of the TPI enzyme. The only SNP located within
the  TPI1  coding sequence (ref. pos. 81309) encodes
Leu121 and is silent; and hence, none of the identified
sequence variants is likely to result in a TPI1 null allele.
This result seems to be inconsistent with a previous study
based on a German population, in which 3000 persons
were screened for reduced TPI activity; 3.7 per 1000 indi-
Table 1: Mutations in the TPI1 gene identified among 357 long-lived individuals. Positions correspond to reference sequence (GenBank 
accession number U47924)
Ref. pos. Variation Flanking site Location Allele Freq. Status
79766 A/T CAGCGCCCTCTCCCG A GGCCCCGAGGCCCCG intron 1 0.004 unknown
79834 G/A GACGAGGGCCGCTGG G GTCCGGGCAGGGGCC intron 1 0.002 unknown
79915 T/C ATGCCCCTTGGACTA T GGGGCAGGTAAGGAC intron 1 0.270 rs2071065
80568 T/C TTGCTCCCTGGAGAA T GCTGAGTCTGTGAGG intron 1 0.001 unknown
81046 T/A CTTCCCTCACTTTCC T CGTTGAGGGGAAAGC intron 2 0.001 unknown
81309 C/T TCTGGCAGAGGGACT C GGAGTAATCGCCTGC exon 4 0.003 unknown
81549 G/C TTGCTTGGGGCCTAT G ACTTCTCCAGCCCCA intron 4 0.001 unknown
81643 G/A ACTCCGGAGAACCTG G CTGGAGAGCTCTTTC intron 4 0.001 unknown
81856 G/A ACACAGCCCACATGG G GCAACCCCTTATTTC intron 5 0.260 rs2071069
81879 del(CA) CTTATTTCAAAGACA CA GAGACCTTGAACCCA intron 5 0.001 unknown
81959 C/T CAGAGCCCTGGTACT C TGACTCAGTCAGAAA intron 5 0.001 unknown
81980 C/G CAGTCAGAAACCACA C TAAGTGTCCACTGGT intron 5 0.025 unknown
81985 T/C AGAAACCACACTAAG T GTCCACTGGTGCCAG intron 5 0.001 unknown
82045 G/A GTCTTACTTAGGCCA G CTTCTTGTTCTAGGC intron 5 0.001 unknown
82214 G/A GCCCTCGGACATGGA G GTGGGGATGGGGCAG intron 6 0.001 unknown
82813 T/C TATGTGAACCACCCA T GTGAGGGAATAAACC exon 7 0.001 unknown
82860 A/G GGTTTGTCTGCCTTC A CTGGACTTGCCCAGA exon 7 0.001 unknownBMC Genetics 2008, 9:38 http://www.biomedcentral.com/1471-2156/9/38
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viduals showed reduced triosephosphate isomerase activ-
ity (in the range of 39 to 76% compared to the enzyme
activity of controls) and were verified to be heterozygous
carriers [14]; even higher frequencies of haploid TPI defi-
ciencies were detected in other populations [11-15]).
However, there are several possible explanations for the
discrepancy of these biochemical screenings with the
results of our sequence analyses. First, it is feasible that the
number of sequenced individuals was too small to detect
the predicted null alleles. Second, the reduced enzyme
activities measured in the previous studies could be, at
least in part, based on factors acting is trans; e.g. mutations
affecting the activity of transcription factors controlling
the expression of the TPI enzyme. Indeed, in the Eber et al.
study, none of the heterozygous persons expressed an
electrophoretic variant of the TPI enzyme [14]. Finally, it
cannot be excluded from our data that inactive TPI alleles
have negative effects on human life expectancy and hence,
would be depleted in the analyzed LLI group. In fact, a
variety of genes increasing the oxidative-stress resistances
in model organisms can, dependent on environmental
conditions, shorten their lifespan, and yeast as well as C.
elegans with reduced TPI activity show indeed shortened
lifespan when growing under standard laboratory condi-
tions [17]. This phenotype might be caused by an
observed shift of the cellular redox potential versus its
reduced state [17], resulting in a condition termed reduc-
tive stress. Remarkably, reductive stress has been found to
be deleterious and disease-causing in mice [23]. Nonethe-
less, our data reveals no enrichment of TPI null alleles
among long-lived individuals, indicating that the poten-
tial heterozygote advantage of the TPI+/0 genotype does not
promote longevity in humans.
For a final answer to all these questions, further studies
have to focus on much larger numbers of studied individ-
uals and on the comparison of TPI allele frequencies in
different age groups and populations. Fortunately, next
generation sequencing technology (e.g. massively parallel
pyrosequencing with 454/Roche FLX system, sequencing
by synthesis with the Illumina/Solexa system or sequenc-
ing by ligation with the Applied Biosystems SOLiD sys-
tem) will allow coping with the required sample
quantities at affordable costs.
Conclusion
In this study, we analyzed and sequenced the TPI1 locus
in a large sample of LLI of German descent. We identified
17 SNPs of which 15 were rare and previously unknown.
None of the identified sequence variations affected the
amino acid composition of the TPI protein and hence,
these mutations are unlikely to impact the catalytic activ-
ity of the enzyme. Thus, genetic TPI variants occur less fre-
quent than expected and inactive TPI alleles are not
enriched in German centenarians.
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